key: cord-0889872-2jc85pi5
authors: C, Selvaa Kumar; Kumar, Senthil Arun; Dasgupta, Debjani; Wei, Haiyan
title: An in-silico based clinical insight on the effect of noticeable CD4 conserved residues of SARS-CoV-2 on the CD4-MHC-II interactions
date: 2020-06-19
journal: bioRxiv
DOI: 10.1101/2020.06.19.161802
sha: 90b693d9ea287140be916006c6323d8930c6c3b9
doc_id: 889872
cord_uid: 2jc85pi5

The study is aimed to unveil the conserved residues of CD4 in the context of its purposeful interaction with MHC-II at the receptor-binding domain (RBD) of SARS-CoV-2 compared with the envelope (Env) glycoprotein (gp) 120 of HIV-1. The paired CD4 conserved residues, including the matched CD4 interacting MHC-II epitopes of the structural viral protein domains, were chosen for the protein modelling using the SWISS-MODEL online server. Energy minimization and structural validation of the modelled viral protein domains, including the CD4 and MHC-II protein were achieved by CHIMERA and PROCHECK-Ramachandran Plot respectively. Protein-protein docking was performed by the HADDOCK online tool. The binding affinity score was measured using the PRODIGY online server. As per our docking report, the Env gp120 of HIV-1 with three identical and three conserved residues of CD4 exhibited the highest binding affinity (−13.9 kcal/mol) with MHC-II than the second-highest RBD-S1-SARS-CoV-2 (−12.5 kcal/mol) with three identical and a single conserved residue of CD4. With a noticeable single salt bridge formation identified at the interacting residues Lys305 (of Env gp120-HIV-1) and Glu139 (of MHC-II); the Env gp120 interaction with MHC-II occupied the crucial His144 and Glu194 (salt-bridge) interacting residues of CD4 with the measured buried surface area 2554.8±40.8 Å2. Similarly, the RBD-S1-SARS-CoV-2-MHC-II complex showed two salt bridge formations at the residue sites: 1) Arg567 (of SARS-CoV-2)-Glu194 (of MHC-II) 2) 2) Asp568(of SARS-CoV-2)-Arg165 (of MHC-II) with the increased buried surface area of 1910.9±97.1 Å2 over the SARS-CoV score 1708.2±50.8 Å2; that camouflaged all crucial CD4 interacting residues of MHC-II. In conclusion, the noticeable conserved residues of CD4 at the RBD-S1 sites of SARS-CoV-2 could interrupt the aspired CD4-MHC-II interactions of adaptive immune activation.

SARS-CoV-2 pandemic has inflicted higher mortality among the global population (SARS-CoV) and human immunodeficiency virus type 1 (HIV-1) [2] . Based on the noticeable clinical symptoms of SARS-CoV-2, experts from the global countries have been widely focusing on all potential SARS-CoV-2-based and human-host based therapeutic targets to control its emerging spread rate as well as its virulence among the humans [3] [4] [5] .

Cytokine storm has been witnessed as one of the major detrimental clinical symptoms of SARS-CoV-2 virulence causing maximum mortality with severe respiratory ailments among the severely ill patients [6] [7] [8] . However, with the noticeable decrease in the production of the anti-inflammatory cytokines, especially IL-4, and its concordant CD4+T

helper cells counts on the SARS-CoV-2 patients [9-12]. It is more likely for the adaptive immune system to get disturbed mimicking the clinical conditions of the HIV-1 affected patients [12] [13] [14] .

MHC-II comprised of two domains α1 and β1 derived from the single heavy-α and -β chains that got slightly curved into a β-sheet conformation at the base (for the peptideantigen binding) with the two α-helices at its top to accommodate the antigenic peptides [15] . The peptide binding unit is further strengthened by the two membrane-proximal immunoglobins (Ig) domains: α2 and β2 adhered to each α1 and β1 heavy chains of MHC-II, respectively [15] . The residues 137-143 of β2-microglobulin domain of MHC-II has been exclusively engaged in interacting with the three exposed loops of the CD4 co- Generally, the HXB2 residues (418-445 residues) spotted at the C-terminal half of the V3 loop of HIV-1 envelope glycoprotein120 (Env gp120) attenuates the adaptive immune response via establishing a stable interaction with the loop 1 (L1) of CD4 [19] [20] [21] .

Moreover, the HIV-1 Env gp120 by adopting the homology residues of CD4 (SLWDQ) and MHC-II (VVSTQLLLNG), attenuated the CD4-MHC-II interactions and its associated adaptive immune response [18] . Similarly, the homologous residues of IL-2 spotted at the human immune deficiency virus (HIV)-viral receptor proteins were proposed to inhibit the IL-2 mediated immune response [22] . Based on these clinical inferences, we speculate that the receptor-binding domain (RBD) of the spike 1 (S1) protein of SARS-CoV-2 might possess the homologous residues of SLWDQ and/or of any conserved residues of the host-CD4 that seals its interaction with the MHC-II.

To prove this, the prevalence of any conserved CD4 binding residues at the RBD of coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2), and as well as at the Env gp120 (V3 loop) site of HIV-1 were carried out using pairwise sequence alignment.

Further, the effect of the existence of any conserved CD4 residues at the RBD sites of coronaviruses in the context of purposeful CD4-MHC-II interactions were studied using the protein-protein docking. The efficacy of the RBD interactions with the MHC-II competing with the CD4 interactions was evaluated based on the Env gp120 (V3 loop) interactions with MHC-II. We believe that SARS-CoV-2 by procuring the crucial conserved binding residues of CD4 with MHC-II could markedly intervene the CD4-MHC-II interactions in the context of adaptive immune activation. Also, all notified CD4

conserved active residues at the RBD sites of SARS-CoV-2 shall be targeted to rejuvenate the disrupted host-adaptive immune response by paving the firm CD4-MHC-II interactions.

The alignment is intended to examine the prevalence of MHC-II interacting CD4- 

The entire downloaded protein sequences of RBD of the S1 protein of coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2) and Env gp120 of HIV-1, including the host-human based MHC-II and CD4 protein sequences were chosen for the homology modelling using the SWISS-MODEL online server [26] . By referring to the enlisted templates, the overall resolution, query coverage and the residue identity were chosen for the homology modelling. All structurally modelled protein structures were subjected to energy minimization followed by its structural validation using CHIMERA [27] and ProSa-Web online server [28] , respectively. Parallelly, all generated protein models were structurally examined by validating its phi-psi plot using the PROCHECK-Ramachandran plot [29] .

Protein-protein docking was performed using the modelled protein structures in the sequential order by the HADDOCK (High Ambiguity Driven protein-protein DOCKing)

online server [30] . HADDOCK has been classified as the information-oriented flexible docking module. In the context of the evaluation of MHC-II-SARS-CoV-2 (antigen) presentation, initially, the protein-protein docking was performed between the human-

coreceptor. Upon this MHC-II-CD4 docking, the active residues engaged in establishing the stable interactions were chosen in each of the MHC-II and CD4 binding domains. The active residues spotted at the CD4 interacting loci includes Arg35, Tyr40, Phe43, Leu44, Trp45, Lys46, Arg59, Ser60 and Asp63. While, the active residues like Leu114, Val116, Val142, Val143, Ser144, Thr145, Ile148, Leu158, Met160 and Glu162 were spotted at the MHC-II interacting loci. Moreover, these active site residues of each MHC-II and CD4

interacting loci, respectively, were procured by the literature review [31] . By default, all passive residues that are generally classified as the surrounding surface residue would be defined and marked by the software on its own. Following the protein-protein docking of each of the RBD of the S1 protein of coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2) and the Env gp120 of HIV-1 with MHC-II was performed sequentially. The HADDOCK score and the buried interface regions were calculated during docking. Since the calculated HADDOCK scores don't have any unit values as such, we have chosen the PRODIGY online server [32] to measure the binding affinity in kcal/mol.

3.1 Pairwise alignment of the human-CD4 with the V3 loop of Env gp120-HIV-1 and the RBD of the S1 protein of coronaviruses.

As evidenced, the crucial CD4-SLWDQ residue has been spotted as the partial segment of the major interface region with the residues Arg35, Tyr40, Phe43, Leu44, Trp45, Lys46, Arg59, Ser60 and Asp63 that profusely strengthens the CD4 interactions with MHC-II [33] . Thus, the entire MHC-II interacting residues from Arg35-Asp63 (residues count 29) of CD4, including the crucial short-SLWDQ residue were chosen for the pairwise alignment. Firstly, to locate the short CD4-SLWDQ residue accompanied with its other flanking (Arg35-Asp63) residues in the V3 loop of Env gp120-HIV-1; the pairwise alignment was performed between the host-human CD4 and the V3 loop of Env gp120-HIV-1. Noticeably, three identical residues with four conservative substitutions with three marked gaps were spotted with the CD4-Env gp120-HIV-1 alignment. Secondly, upon the pairwise alignment performed between the human-CD4 and the RBD of the S1 protein of SARS-CoV, its neither the identical residues nor the conservative substitutions were 

The protein sequences of CD4, MHC II, Env gp120-Hiv, SARS-CoV and SARS-CoV-2 were chosen for model building respectively. The most preferred template for 3D modelling of Env gp120-HIV-1 was PDB ID: 3J70 [34] ) with 97.01% sequence identity and 97% query coverage; PDB ID: 6acd [35] ) with 99.925 % sequence identity and 95%

query coverage for SARS-CoV (RBD of S1); PDB ID: 6m18 chain B [36] ) with 100 % sequence identity and 99% query coverage for SARS-CoV-2 (RBD of S1); PDB ID: 1JL4 [37] ) with missing residues for human-CD4; PDB ID: 4Z7U [38] with 100% sequence 

The HADDOCK score generated upon MHC-II-CD4 docking was lower (-100.7±-2.9) than the HADDOCK score value of MHC-II-Env gp120-HIV-1 complex (-111.1±-3.8) and

the RBD-SARS-CoV-2 complex (-122.1±-5.0). The HADDOCK score value of the MHC-II-RBD-SARS-CoV complex was the least amongst all the structural viral study proteins with the score value of -55.7±-5.5 (in the complete state) and -84.0±-2.6 (in the trimmed state). Nevertheless, of all the studied proteins, the highest HADDOCK score value was recorded with the MHC-II-RBD-S1-SARS-CoV-2 complex. Commonly, the HADDOCK score value is the culmination of the energies measured by the OPLS force field-based electrostatics and the Van der walls accompanied by the evaluation of the buried surface area and desolvation.

It is quite obvious that a firm conclusion on the docking results could have arrived only after the comparative analysis of all diverse data generated for each study protein complexes. For the same reason, we have adopted the PRODIGY online server tool to estimate the binding affinity of all the docked protein complexes. The PRODIGY analysis showed the least binding affinity score value (-9.4 kcal/mol) of the MHC-II-CD4 protein complex. While the MHC-II-Env gp120-HIV-1 complex showed the highest binding affinity (-13.9 kcal/mol) followed by the MHC-II-RBD-S1-SARS-CoV-2 complex (-12.5 kcal/mol) and the MHC-II-RBD-S1-SARS-CoV ((-11.9 kcal/mol (in the complete state) and -11.8 kcal/mol (in the trimmed state)).

In terms of the buried surface area, the MHC-II-CD4 complex has recorded the least score Table 2) .

SARS-CoV-2 pandemic has emerged as a dreadful human threat with the increasing number of casualties of the death toll of 430, 133 (as of 14 th June 2020) across the global countries (https://www.worldometers.info/coronavirus/). SARS-CoV-2 being remarkably contagious than the highly virulent MERS-CoV and SARS-CoV strains, clinicians have been struggling to either control its spread rate or its virulence among the global population [39, 40] . Clinical therapeutic targets of either host-based or the direct SARS-CoV-2-based, especially its spike1 glycoprotein (S1)-receptor binding domain (RBD) have been widely pronounced for the development of vaccines and/or other natural therapeutic bio-actives against the SARS-CoV-2 virulence [41, 42] . However, clinicians are yet struggling to find any promising biological targets because of the diverse clinical characteristics of SARS-CoV-2 [43, 44] . Of all noticeable clinical symptoms, the cytokine storm and the diminished CD4+T helper cells production have been remarkably noticed among the infected patients [12, 45] . Moreover, therapeutic targets in the context of the adaptive immune response regulated by the MHC-II antigen presentation of SARS-CoV-2 remains unexplored demanding more research studies in this clinical perspective [45, 46] . We believe that any modules of clinical targets linked with the adaptive immunity to be crucial to tackle the emerging spread rate as well as the pathogenesis of SARS-CoV-2 [46] .

Having enlightened on a diverse range of epitopes at the S1-RBD site of SARS-CoV-2 that residues of CD4 co-receptor at the S1-RBD site of SARS-CoV-2 could disturb the adaptive immune system by intervening the CD4-MHC-II interactions.

While seeking the prevalence of any CD4 conserved residues (Arg35, Tyr40, Phe43, Leu44, Trp45, Lys46, Arg59, Ser60 and Asp63), including the CD4 homology residues of SLWDQ, and its MHC-II interacting epitopes SSKRFQPFQQFGRDV at the RBD of SARS-CoV viruses (Figure 2a-d) [18,23]; We found the procurement of CD4 conserved residues such as Arg567 and Asp568 accompanied with the CD4 interacting MHC-II epitopes (SNKKFLPFQQ-FGRDI) by the RBD-SARS-CoV-2 has facilitated the stable salt bridge formations with the Glu194 and Arg165 residues of MHC-II, respectively (Table 2) .

Following, the Env gp120-HIV-1 has recorded the highest binding affinity score for MHC-II amongst all viral study proteins. However, the human-CD4 showed the least binding affinity score for MHC-II with the two noticeable salt bridge formations. The Env gp120-HIV-1 has established a single salt bridge formation with the MHC-II. With this interaction, the entire CD4 interacting residues (marked using *) of MHC-II has been occupied with the Env gp120-HIV-1 binding with the highest buried surface area. Similarly, the RBD-SARS-CoV-2 binding with MHC-II has enclaved its crucial CD4 interacting residues such as His144 and Glu194

with the second-highest buried surface area. Moreover, the RBD-SARS-CoV binding has accommodated all crucial CD4 interacting residues with the MHC-II (marked in *), showed a higher binding affinity and the buried surface area than the CD4-MHC-II complex.

Combinedly, the RBD-SARS-CoV-2 that possessed three identical residues with one conserved residue of CD4 has established a stable interaction with the MHC-II akin to the Env gp120-HIV-1 with three identical residues and three conserved residues. However, the RBD-SARS-CoV by procuring the CD4-interacting MHC-II epitopes: SSKRFQPFQQFGR-DV established a strong interaction with MHC-II compared with human CD4-MHC-II interactions, but showed a weak interaction compared with the HIV-1 and SARS-CoV-2 ( Figure 2a , Table   1 ). This may be due to the absence of any noticeable CD4 conserved residues at the RBD- 

A scale-free analysis of the HIV-1 genome demonstrate multiple conserved regions of structural and functional importance

Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization

Rapid and selective depletion of CD4+ T lymphocytes and preferential loss of memory cells on the interaction of mononuclear cells with HIV-1 glycoprotein-expressing cells

Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2

Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv

The SWISS-PROT protein sequence data bank and its new supplement TREMBLE

Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega

SWISS-MODEL: homology modelling of protein structures and complexes

UCSF Chimera--a visualization system for exploratory research and analysis

ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins

PROCHECK: a program to check the stereochemical quality of protein structures

The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes

Affinity maturation of human CD4 by yeast surface display and crystal structure of a CD4-HLA-DR1 complex

Large-scale prediction of binding affinity in protein-small ligand complexes: the PRODIGY-LIG web server

Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis

Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule

Determinants of gliadin-specific T cell selection in celiac disease

Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties

SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention

An Update on Current Therapeutic Drugs Treating COVID-19

Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV

Emerging genetic diversity among clinical isolates of SARS-CoV-2: Lessons for today

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

Molecular immune pathogenesis and diagnosis of COVID-19

Preliminary Identification of Potential Vaccine Targets for the COVID-19

SARS-CoV-2) Based on SARS-CoV Immunological Studies

Potential T-cell and B-cell Epitopes of 2019-nCoV. bioRxiv

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Figure Legends: 1. Structural illustration of the CD4-bound MHC-II complex shown in ribbon module. The D1 domain of CD4 comes in proximity with the β domain of MHC-II

SARS-CoV-2, and MERS-CoV) and the envelope (Env) glycoprotein (gp) 120 of HIV-1. The underlined short nucleotide motif SLWDQ is linked with the immunosuppression. Exome highlighted in red font implies the MHC-II conserved epitopes. All noticeable amino acid residues of the above-mentioned structural viral proteins, including the human-CD4 domain residues that are indulged in stable interactions with MHC-II, have been highlighted using downward black arrows ( ). Homology residues spotted with the paired nucleotides have been marked using an asterisk (*) symbol

Amino acids with weak substitutions have been spotted by a single dot

Protein-protein docking of the structural viral membrane proteins with the CD4. (a) Structural representation of the envelope (Env) glycoprotein (gp

The authors would like to acknowledge technical support from the School of Biotechnology and Bioinformatics, D.Y. Patil Deemed to be University, CBD Belapur for providing access to the softwares for biological data analysis. This work was not funded by any external funding agencies.